drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified autologous T cells)
drug_description
Autologous CMV-specific T cells genetically modified via lentiviral transduction to express a chimeric antigen receptor (CAR) targeting HIV-1 gp120, incorporating an EGFR tag for selection/safety. Administered intravenously (5–50 million EGFR+ cells). CAR engagement triggers T-cell activation and cytotoxic killing of HIV-infected cells; endogenous CMV-specific TCR signaling supports expansion and persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CMV-specific T cells are lentivirally engineered to express a CAR that binds HIV-1 gp120. Upon recognizing gp120 on HIV-infected cells, the CAR activates the T cells to proliferate and kill targets via perforin/granzyme cytotoxicity and cytokine release. The cells retain their endogenous CMV-specific TCR, enabling CMV-driven stimulation to enhance expansion and persistence in vivo. An EGFR tag allows cell selection and potential safety depletion.
drug_name
Autologous CMV/HIV-CAR T cells
nct_id_drug_ref
NCT06252402